Collaboration to develop innovative therapeutic antibodies using Genuv's proprietary mouse platform for antibody discovery.
CAMBRIDGE, Mass., March 15, 2023 /PRNewswire-PRWeb/ -- Genuv Inc., a clinical-stage biotechnology company focused on drug discovery, and Celltrion, a leading global biopharmaceutical company, have entered into a partnership to jointly discover and develop novel therapeutic antibodies using Genuv's proprietary SHINE MOUSE platform.
The partnership underscores Celltrion's commitment to best-in-class or first-in-class antibody therapies and affirms Genuv's expertise in innovative drug discovery. Under the terms of agreement, Genuv will conduct antibody discovery service using the SHINE MOUSE technology to be followed by research collaboration. If Celltrion exercises its option for joint research and development projects, the agreed milestones are: development milestones up to $25 million followed by total commercial milestones up to $680 million in case of accumulated $7.5 billion sales of per candidate antibody.
The SHINE MOUSE platform generates antibodies with greater diversity compared to conventional mice, which led to the discovery of the experimental, novel anti-PD-1 monoclonal antibody, GNUV201. GNUV201 has the unique feature of exceptional interspecies cross-reactivity and binding affinity allowing preclinical disease animal model studies with increased clinical relevance. Additionally, Genuv is developing GNUV205, an improved IL-2-based immunocytokine anticancer drug that is made tumor-specific by leveraging the properties of GNUV201. Genuv currently has NuvoFc platform, which enables the design and discovery of new bi-/multi-specifics. Furthermore, the NuvoMab platform, which directly discovers human antibodies, is nearing completion of development.
"We are excited to embark on our mouse platform business with Celltrion as our first partner," said Sungho Han, Ph.D., founder and CEO of Genuv. "We believe Celltrion's in-depth knowledge and experiences in antibody development and production and Genuv's expertise in novel antibody discovery with our SHINE MOUSE platform could generate great synergies in providing innovative antibody therapeutics."
Kisung Kwon, Head of R&D unit of Celltrion said, "Celltrion is continuously interested in antibody-based new drugs and anticipates to discover differentiated antibodies through innovative antibody discovery platform technology. We look forward to partnering with Genuv for the development of innovative antibody therapeutics that will bring new hope to patients with high unmet needs."
Media Contact
Ji-Young Yoon / COO, Genuv, Inc., 1 (617) 642-6274, [email protected]
SOURCE Genuv, Inc.
Share this article